For research use only. Not for therapeutic Use.
Ibipinabant (Cat.No:I007243), also known as BMS-646256, JD-5001 and SLV-319, is a potent and highly selective CB1 antagonist. It has potent anorectic effects in animals, and was researched for the treatment of obesity, although CB1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagonists.
| Catalog Number | I007243 |
| CAS Number | 464213-10-3 |
| Synonyms | BMS-646256; BMS646256; BMS 646256; SLV-319; SLV 319; SLV319; JD-5001; JD 5001; JD5001; Ibipinabant.;(E)-(4S)-3-(4-Chlorophenyl)-N/’-((4-chlorophenyl)sulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide |
| Molecular Formula | C23H20Cl2N4O2S |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| IUPAC Name | (4S)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N/'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide |
| InChI | InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m1/s1 |
| InChIKey | AXJQVVLKUYCICH-OAQYLSRUSA-N |
| SMILES | CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
| Reference | </br>1:Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant-induced myotoxicity. Schirris TJ, Ritschel T, Herma Renkema G, Willems PH, Smeitink JA, Russel FG.Sci Rep. 2015 Sep 29;5:14533. doi: 10.1038/srep14533. PMID: 26416158 Free PMC Article</br>2:JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Chorvat RJ, Berbaum J, Seriacki K, McElroy JF.Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80. doi: 10.1016/j.bmcl.2012.08.004. Epub 2012 Aug 20. PMID: 22959249 </br>3:Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant. Leane MM, Sinclair W, Qian F, Haddadin R, Brown A, Tobyn M, Dennis AB.Pharm Dev Technol. 2013 Mar-Apr;18(2):359-66. doi: 10.3109/10837450.2011.619544. Epub 2012 Jan 23. PMID: 22268601 </br>4:Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Rohrbach K, Thomas MA, Glick S, Fung EN, Wang V, Watson L, Gregory P, Antel J, Pelleymounter MA.Diabetes Obes Metab. 2012 Jun;14(6):555-64. doi: 10.1111/j.1463-1326.2012.01563.x. Epub 2012 Feb 24. PMID: 22268426 </br>5:Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by fourier transform raman spectroscopy. Sinclair W, Leane M, Clarke G, Dennis A, Tobyn M, Timmins P.J Pharm Sci. 2011 Nov;100(11):4687-99. doi: 10.1002/jps.22658. Epub 2011 Jun 16. PMID: 21681752 </br>6:Pooled sample strategy in conjunction with high-resolution liquid chromatography-mass spectrometry-based background subtraction to identify toxicological markers in dogs treated with ibipinabant. Zhang H, Patrone L, Kozlosky J, Tomlinson L, Cosma G, Horvath J.Anal Chem. 2010 May 1;82(9):3834-9. doi: 10.1021/ac100287a. PMID: 20387806 |
